AUTHORS
John O. Mascarenhas, MD, Uma Borate, MBBS, MSc2, Prithviraj Bose, MD3, Jacqueline S. Garcia, MD4, Jason Gotlib, MD,MS5, Michael R. Grunwald, MD6, Gabriela Soriano Hobbs, MD7, Andrew T Kuykendall, MD8, Ruben Mesa, MD9, Stephen Oh, MD, PhD10, Kristen Pettit, MD11, Raajit K. Rampal, MD, PhD12, William Shomali, MD13, Andrew Srisuwananukorn, MD14, Eric Vick, MD,PhD15, Abdulraheem Yacoub, MD16, Ana Triguero17, Valentín García Gutiérrez I, MD18, Jean-Jacques Kiladjian19, Ying (denise) Wang20, Negin Ashki, MD, PhD21, Ananya Guntur, PhD22, Shyamala Navada, MD and MSCR23, David Peter Steensma, MD24
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Stanford University, Stanford, California, United States
6 Atrium-Levine/ Wake Forest Cancer Center / Advocate Health, Charlotte, North Carolina, United States
7 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
8 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
9 Atrium-Levine/ Wake Forest Cancer Center / Advocate Health, Charlotte, North Carolina, United States
10 Washington University School of Medicine, St. Louis, Missouri, United States
11 University of Michigan, Ann Arbor, Michigan, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Stanford University, Stanford, California, United States
14 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
15 University of Cincinnati, Cincinnati, Ohio, United States
16 University of Kansas Medical Center, Kansas City, Kansas, United States
17 Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
18 Hospital Ramon y Cajal. IRYCIS. Universidad de Alcalá, Madrid, Spain
19 Centre d'investigation clinique, Hopital St Louis, Paris, France
20 Eli Lilly and Company, Indianapolis, Indiana, United States
21 Eli Lilly and Company, Indianapolis, Indiana, United States
22 Eli Lilly and Company, Indianapolis, Indiana, United States
23 Eli Lilly and Company, Indianapolis, Indiana, United States
24 Ajax Therapeutics, New York, New York, United States
ABSTRACT
Background: Aberrant JAK-STAT signaling in clonal hematopoietic stem and progenitor cells drives myelofibrosis (MF) and is the therapeutic target for approved type I JAK2 inhibitors (JAK2i). Despite spleen and symptom benefit, many patients (pts) discontinue JAK2i therapy within ~3 years (yrs) of initiation due to progression or toxicity; effective options thereafter are limited (Palandri F et al Cancer 2020). LY5830966 (formerly AJ1-11095) is a novel orally bioavailable small molecule type II JAK2i that inhibits both JAK2 homodimerization and heterodimerization with JAK1 and TYK2, overcoming a common mechanism of clonal persistence and drug resistance to type I JAK2i. We report updated dose escalation and dose expansion results from the first-in-human clinical trial (NCT06343805) of LY5830966 in pts with MF who have been failed by a type I JAK2i but had recurrent or persistent splenomegaly and symptoms.
Methods: Key eligibility criteria included MF with ≤10% marrow blasts; DIPSS intermediate-2 or high-risk disease; spleen volume ≥450cm3; Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 Total Symptom Score (TSS) ≥10 or ≥2/7 symptoms scoring ≥3; relapsed/refractory after prior therapy with ≥1 type I JAK2i; baseline platelet count ≥75 x 109/L; and adequate organ function. The study included dose escalation (part 1) and dose expansion (part 2). Intra-pt dose escalation was permitted after 24 weeks (wks). The primary objective is to evaluate safety (CTCAE v5.0) and establish the maximum tolerated dose and/or recommended phase 3 dose for LY5830966. Secondary endpoints include rates of ≥50% reduction in TSS (TSS50) and ≥35% reduction in spleen volume (SVR35) from baseline to Wk24. Exploratory endpoints include the Patient Global Impression of Change (PGIC), and biomarker changes from baseline, including JAK2 variant allele frequency (VAF) and other clonal markers. The efficacy evaluable population for each endpoint included treated pts with a valid baseline and ≥1 post-baseline assessment for that endpoint (spleen volume for SVR; MFSAF TSS for TSS), or who discontinued treatment before the first post-baseline assessment. Pts without a valid MFSAF baseline were excluded from TSS analyses only. Evaluable N may differ between SVR and TSS at a given time point due to differing assessment schedules. Data cutoff: June 19, 2026.
Results: In part 1, 23 pts received LY5830966 at doses of 25 (n=3), 50 (n=3), 75 (n=6), 100 (n=6), or 125 mg (n=5) orally once daily; in part 2, 30 pts received LY5830966 75 mg once daily as of the data cutoff. Of the 53 treated pts, the median age was 69 yrs (range, 47-87); 68% male; median number of prior lines of therapy was 3 (range, 1-10); median time from diagnosis was 4 yrs (range, 0-19); mean baseline MFSAF TSS (SD) was 26 (13). Fifty-one (96%) pts had prior ruxolitinib; 21 (40%) had prior momelotinib. At data cutoff, 48/53 pts remain on therapy, with a median time on therapy of 5 months (mo; range, 1.2-20.9). Any grade (G) TEAEs occurred in 94% of pts and G≥3 TEAEs in 62%; anemia (47%; G≥3, 40%; though pts generally had low baseline Hgb levels), dysgeusia (32%; G≥3, 0%), and diarrhea (28%; G≥3, 2%) were the most common TEAEs. Any G TRAEs and G≥3 TRAEs occurred in 77% and 42% of pts, respectively. Dose reductions and discontinuations due to TEAEs occurred in 25% and 2% of pts, respectively; no treatment-related deaths were reported.
With more recent part 2 enrollment (median time on study, 4 mo vs 11 mo for part 1), Wk24 data are available for part 1 only. In part 1, 13 of 23 (57%) pts evaluable at Wk24 achieved SVR35, and 14/23 (61%) achieved SVR25. TSS50 was achieved in 11/19 (58%) pts at Wk12 and 12/19 (63%) at Wk24, with mean absolute TSS changes (SD) from baseline of -14.9 (8.6) and -18.5 (12.0), respectively. In part 2, 9/15 (60%) pts evaluable at Wk12 achieved SVR35, and 13/15 (87%) achieved SVR25. TSS50 was achieved in 10/26 (39%) pts at Wk4 and 9/17 (53%) at Wk12, with mean absolute TSS changes (SD) from baseline of -11.0 (10.0) and -13.5 (11.0), respectively. Updated PGIC and driver mutation VAF reduction data will be reported at ASH 2026.
Conclusion: LY5830966, a first-in-class type II JAK2i, demonstrated clinically meaningful spleen and symptom responses and a manageable safety profile in a heavily pretreated MF population that had been failed by prior type I JAK2i therapy, supporting continued development and further evaluation of its disease-modifying potential.
DISCLOSURES
John O. Mascarenhas, MD: Italfarmaco Spa - Research Funding; Incyte - Research Funding; Geron - Research Funding; Dompe - Research Funding; DISC - Research Funding; Karyopharm - Research Funding; Novartis - Research Funding; PharmaEssentia - Research Funding; SOBI - Research Funding; Takeda - Research Funding; BMS - Research Funding; Kartos - Research Funding; Galecto - Research Funding; Kartos - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Italfarmaco Spa - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony); Damora - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); MorphoSys - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); DISC - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony); Keros - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Galecto - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony)